当前位置：
X-MOL 学术
›
Aliment. Pharm. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2021-10-25 , DOI: 10.1111/apt.16663 Cristina Bezzio 1 , Alessandro Armuzzi 2 , Federica Furfaro 3 , Sandro Ardizzone 4 , Monica Milla 5 , Sonia Carparelli 6 , Ambrogio Orlando 7 , Flavio Andrea Caprioli 4 , Fabiana Castiglione 8 , Chiara Viganò 9 , Davide Giuseppe Ribaldone 10 , Fabiana Zingone 11 , Rita Monterubbianesi 2 , Nicola Imperatore 8 , Stefano Festa 2 , Marco Daperno 10 , Ludovica Scucchi 2 , Antonio Ferronato 12 , Luca Pastorelli 4 , Paola Balestrieri 2 , Chiara Ricci 13 , Maria Cappello 7 , Carla Felice 14 , Gionata Fiorino 3 , Simone Saibeni 1 ,
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2021-10-25 , DOI: 10.1111/apt.16663 Cristina Bezzio 1 , Alessandro Armuzzi 2 , Federica Furfaro 3 , Sandro Ardizzone 4 , Monica Milla 5 , Sonia Carparelli 6 , Ambrogio Orlando 7 , Flavio Andrea Caprioli 4 , Fabiana Castiglione 8 , Chiara Viganò 9 , Davide Giuseppe Ribaldone 10 , Fabiana Zingone 11 , Rita Monterubbianesi 2 , Nicola Imperatore 8 , Stefano Festa 2 , Marco Daperno 10 , Ludovica Scucchi 2 , Antonio Ferronato 12 , Luca Pastorelli 4 , Paola Balestrieri 2 , Chiara Ricci 13 , Maria Cappello 7 , Carla Felice 14 , Gionata Fiorino 3 , Simone Saibeni 1 ,
Affiliation
|
Older age and comorbidities are the main risk factors for adverse COVID-19 outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications is still under investigation.
中文翻译：
炎症性肠病的治疗不会对 SARS-CoV-2 感染的不良后果构成额外风险：一项 IG-IBD 研究
高龄和合并症是炎症性肠病 (IBD) 患者 COVID-19 不良结局的主要危险因素。IBD 药物的影响仍在调查中。
更新日期：2021-11-07
中文翻译：
炎症性肠病的治疗不会对 SARS-CoV-2 感染的不良后果构成额外风险：一项 IG-IBD 研究
高龄和合并症是炎症性肠病 (IBD) 患者 COVID-19 不良结局的主要危险因素。IBD 药物的影响仍在调查中。
京公网安备 11010802027423号